7 Pulmonary Fibrosis Headlines


3. Potential IPF Treatment, a LOXL2 Inhibitor, Showing Benefits in Preclinical Work


Synairgen, plc, recently reported positive data from its ongoing work, in partnership with Pharmaxis, to develop a lysyl oxidase-type 2 enzyme (LOXL2) inhibitor as a new treatment for idiopathic pulmonary fibrosis (IPF). The results were derived from experiments in an in vitro model of IPF, using patients’ lung cells, conducted in association with researchers at the University of Southampton, United Kingdom.

Read more about it: http://bit.ly/1SgAzCg

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *